NCT07532603 A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
| NCT ID | NCT07532603 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Priovant Therapeutics, Inc. |
| Condition | Lichen Planopilaris |
| Study Type | INTERVENTIONAL |
| Enrollment | 342 participants |
| Start Date | 2026-03-19 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 342 participants in total. It began in 2026-03-19 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. Scalp biopsy consistent with LPP 3. Active and symptomatic LPP at screening and baseline- 4. Weight \> 40 kg to \< 130 kg with BMI ≤ 45 kg/m2 Exclusion Criteria: 1. History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer). 2. High risk of thrombosis or cardiovascular disease 3. High risk of herpes zoster 4. Active or recent infection
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07532603 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lichen Planopilaris. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07532603 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07532603 currently recruiting?
Yes, NCT07532603 is actively recruiting participants. Contact the research team at clinicaltrials@priovant.com for enrollment information.
Where is the NCT07532603 trial being conducted?
This trial is being conducted at Birmingham, United States, Phoenix, United States, Scottsdale, United States, Irvine, United States and 11 additional locations.
Who is sponsoring the NCT07532603 clinical trial?
NCT07532603 is sponsored by Priovant Therapeutics, Inc.. The trial plans to enroll 342 participants.